Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Inclusion Criteria:

- Outpatient

- 18 years of age or older at Visit 1

- Diagnosis of Asthma

- Male or eligible Female

- Pre-bronchodilator FEV1 of 40-80% of the predicted normal value at Visit 1

- Demonstrated reversibility by ≥12% and ≥200mL of FEV1 within 40 minutes following
albuterol at Visit 1

- A need for regular controller therapy (i.e., inhaled corticosteroids alone or in
combination with a long‐acting beta‐agonist, or leukotriene modifier etc.,) for a
minimum of 8 weeks prior to Visit 1.

Exclusion Criteria:

- History of Life threatening asthma

- Respiratory infection not resolved

- Asthma exacerbation

- Concurrent respiratory disease

- Current Smokers

- Other diseases that are uncontrolled disease or disease state that, in the opinion of
the investigator, would put the safety of the patient at risk through study
participation or would confound the interpretation of the efficacy results if the
condition/disease exacerbated during the study

- A positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV

- Visual clinical evidence of oropharyngeal candidiasis

- Drug or milk protein allergies

- Concomitant medications affecting course of asthma

- Use of any other investigational medication within 30 days or 5 drug half-lives
(whichever is longer)

- Previous use of GSK573719

- Any disease preventing use of anticholinergics

- Any condition that impairs compliance with study protocol including visit schedule and
completion of daily diaries

- Any subject with a history of alcohol or substance abuse

- Any affiliation with Investigator's site